Evaluation of Prostacare EF (Excipient free) In benign prostatic enlargment

A double blind placebo control clinical trial to Evaluate the efficacy of Prostacare EF In benign prostatic hypertrophy

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2011/06/001797

Enrollment

Registered

2011-06-10

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Benign prostatic hypertrophy

Interventions

Intervention1: Prostacare EF: Dose - 2 capsule of Prostacare EF twice daily Duration of treatment - 3 months Mode of administration - oral Control Intervention1: Placebo: Dose - 2 capsule of placebo t

Eligibility

Inclusion criteria

Inclusion criteria: Males between 40-60 years of age suffering from benign prostatic hypertrophy.

Exclusion criteria

Exclusion criteria: Males less than 40 years old are excluded from the trial.

Design outcomes

Primary

Measure	Time frame
Improvement in the symptoms of BPH as measured by American Urological Association (AUA) symptom score.Timepoint: 3 months	—

Secondary

Measure	Time frame
Assessment of long term safety of the study drug.Timepoint: 3 months	—

Countries

India

Contacts

Public ContactDr A K Singh

doctoraksingh@yahoo.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026